{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:10:15Z","timestamp":1790079015663,"version":"4.0.1"},"reference-count":41,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Sj\u00f6gren\u2019s disease (SjD) causes severe ocular surface desiccation, progressing from aqueous-deficient dry eye (ADDE) to vision-threatening corneal ulceration, stromal melting, and perforation. Recent consensus guidelines and therapeutic innovations have transformed ophthalmic diagnosis and management. Methods: A comprehensive narrative overview of PubMed and Google Scholar (July 2016\u2013July2026) was conducted to evaluate updates in SjD diagnostics, ocular surface mechanics, topical\/biological pharmacotherapies, neurostimulation, and meibomian gland interventions. Results: Diagnostic parameters have shifted towards non-invasive salivary metabolomics (lactate, alanine, malate), regulatory non-coding RNAs (H19 ICR hypomethylation), tear point-of-care MMP-9 testing, and salivary gland ultrasonography (SGUS). Large-diameter scleral lenses provide continuous corneal fluid shielding, though edge design and surface modification are required to mitigate midday fogging. Additionally, emerging therapeutics are shifting care from palliative lubrication to targeted secretomotor and biological reactivation, including cold thermosensory TRPM8 agonists (acoltremon 0.003%), water-free formulations (0.1% cyclosporine, perfluorohexyloctane), reactive aldehyde species (RASP) modulators (reproxalap), syndecan-1 receptor agonists (Lacripep), systemic B-cell depleting biotherapy (ianalumab), trigeminal neurostimulation, and combined intense pulsed light with meibomian gland expression (IPL + MGX). Conclusions: Ophthalmic SjD management has evolved from palliative lubrication toward a stepwise, mechanism-directed paradigm integrating novel diagnostics, secretomotor stimulation, mechanical protection, and biologic disease modification; dedicated SjD-specific trials remain essential to validate these emerging interventions.<\/jats:p>","DOI":"10.3390\/jcm15187272","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:09:35Z","timestamp":1790075375000},"page":"7272","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ophthalmic Treatments and Evolving Management of Sj\u00f6gren\u2019s Disease: An Overview"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5345-1755","authenticated-orcid":false,"given":"Mar\u00eda Garc\u00eda","family":"Forestier","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, University of Puerto Rico, San Juan 00936-5067, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7981-1687","authenticated-orcid":false,"given":"Jos\u00e9","family":"Nassar Badillo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, University of Puerto Rico, San Juan 00936-5067, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7533-6121","authenticated-orcid":false,"given":"Armando L.","family":"Oliver","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, School of Medicine, University of Puerto Rico, San Juan 00936-5067, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"ref_1","unstructured":"American Academy of Ophthalmology (2026, August 02). What Is Sj\u00f6gren\u2019s Syndrome? EyeSmart [Internet]. Reviewed by Huffman, J.M. Available online: https:\/\/www.aao.org\/eye-health\/diseases\/what-is-sjogren-syndrome."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41584-025-01268-z","article-title":"2023 International Rome consensus for the nomenclature of Sj\u00f6gren disease","volume":"21","author":"Baer","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Roszkowska, A.M., Oliverio, G.W., Aragona, E., Inferrera, L., Severo, A.A., Alessandrello, F., Spinella, R., Postorino, E.I., and Aragona, P. (2021). Ophthalmologic Manifestations of Primary Sj\u00f6gren\u2019s Syndrome. Genes, 12.","DOI":"10.3390\/genes12030365"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5114\/reum.2019.89520","article-title":"Classification criteria for secondary Sj\u00f6gren\u2019s syndrome. Current state of knowledge","volume":"57","author":"Sebastian","year":"2019","journal-title":"Reumatologia"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Meng, Q., Ma, J., Cui, J., Gu, Y., and Shan, Y. (2024). Subpopulation dynamics of T and B lymphocytes in Sj\u00f6gren\u2019s syndrome: Implications for disease activity and treatment. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1468469"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II Definition and Classification Report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e14641","DOI":"10.1097\/MD.0000000000014641","article-title":"Characteristics of dry eye in patients with pre-existing Sj\u00f6gren\u2019s syndrome according to the revised 2016 ACR-EULAR classification criteria","volume":"98","author":"Yoon","year":"2019","journal-title":"Medicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajo.2020.12.019","article-title":"Ocular Involvement in Sj\u00f6gren Syndrome: Risk Factors for Severe Visual Impairment and Vision-Threatening Corneal Complications","volume":"225","author":"Singh","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Qiu, S.X., Fadel, D., and Hui, A. (2024). Scleral Lenses for Managing Dry Eye Disease in the Absence of Corneal Irregularities: What Is the Current Evidence?. J. Clin. Med., 13.","DOI":"10.3390\/jcm13133838"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ophtha.2025.09.018","article-title":"Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal COMET-2 and COMET-3 Studies","volume":"133","author":"Pattar","year":"2026","journal-title":"Ophthalmology"},{"key":"ref_11","unstructured":"(2026, August 02). Two Arm, Double-Blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants with Sj\u00f6gren\u2019s Disease with High Symptom Burden (THALASSA). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07621809?tab=study."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lis, V.E., Skutnik-Radziszewska, A., Zalewska, E., and Zalewska, A. (2025). Salivary Biomarkers for the Diagnosis of Sj\u00f6gren\u2019s Syndrome: A Review of the Last Decade. Biomedicines, 13.","DOI":"10.3390\/biomedicines13112664"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/OARRR.S284763","article-title":"Salivary Gland Ultrasound in Primary Sj\u00f6gren\u2019s Syndrome: Current and Future Perspectives","volume":"14","author":"Lorenzon","year":"2022","journal-title":"Open Access Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clim.2017.04.017","article-title":"Sjogren\u2019s syndrome from the perspective of ophthalmology","volume":"182","author":"Kuklinski","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Nunziata, S., Petrini, D., Dell\u2019Anno, S., Barone, V., Coassin, M., and Zazzo, A.D. (2024). Customized Scleral Lenses: An Alternative Tool for Severe Dry Eye Disease\u2014A Case Series. J. Clin. Med., 13.","DOI":"10.3390\/jcm13133935"},{"key":"ref_16","unstructured":"Carsons, S.E., and Blum, M.A. (2026, July 12). Sjogren Disease, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK431049\/."},{"key":"ref_17","unstructured":"Wu, K.Y., and Faucher, A. Understanding and Managing Sj\u00f6gren Syndrome Dry Eye. EyeNet Magazine. American Academy of Ophthalmology; 2023. Available online: https:\/\/www.aao.org\/eyenet\/article\/understanding-managing-sjogren-syndrome-dry-eye."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Price, E.J., Hallang, S., and Smith, G. (2026). Practical Guide to the Local Treatment of Sjogren\u2019s Disease. J. Clin. Med., 15.","DOI":"10.3390\/jcm15031078"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e001516","DOI":"10.1136\/rmdopen-2020-001516","article-title":"Application of the OMERACT Grey-scale Ultrasound Scoring System for salivary glands in a single-centre cohort of patients with suspected Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Fana","year":"2021","journal-title":"RMD Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II Management and Therapy Report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_21","unstructured":"(2026, August 02). Alcon Announces FDA Approval of Tryptyr (Acoltremon Ophthalmic Solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease. Alcon. Available online: https:\/\/investor.alcon.com\/news-and-events\/press-releases\/news-details\/2025\/Alcon-Announces-FDA-Approval-of-TRYPTYR-acoltremon-ophthalmic-solution-0-003-for-the-Treatment-of-the-Signs-and-Symptoms-of-Dry-Eye-Disease\/default.aspx."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.2147\/OPTH.S312108","article-title":"Efficacy of an Intranasal Tear Neurostimulator in Sj\u00f6gren Syndrome Patients","volume":"15","author":"Lilley","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40123-022-00616-6","article-title":"Effectiveness of Intranasal Tear Neurostimulation for Treatment of Dry Eye Disease: A Meta-Analysis","volume":"12","author":"Li","year":"2023","journal-title":"Ophthalmol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2147\/OPTH.S512364","article-title":"Varenicline Solution Nasal Spray for the Treatment of Dry Eye Disease in Sjogren\u2019s Disease: A Pilot Study","volume":"19","author":"Gupta","year":"2025","journal-title":"Clin. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaophthalmol.2024.0101","article-title":"Water-Free Cyclosporine Ophthalmic Solution vs Vehicle for Dry Eye Disease: A Randomized Clinical Trial","volume":"142","author":"Peng","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100938","DOI":"10.1016\/j.xops.2025.100938","article-title":"Reproxalap Improves Ocular Redness, Tear Production, and Symptoms in a Pivotal Dry Eye Disease Chamber Trial","volume":"6","author":"Garg","year":"2026","journal-title":"Ophthalmol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lee, C., Edman, M.C., Laurie, G.W., Hamm-Alvarez, S.F., and MacKay, J.A. (2020). Biosynthesized Multivalent Lacritin Peptides Stimulate Exosome Production in Human Corneal Epithelium. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176157"},{"key":"ref_28","unstructured":"(2026, September 06). Novaliq and Laboratoires Th\u00e9a Announce Partnership and EU Approval for Vevizye (Ciclosporin 0.1% Eye Drops Solution). Available online: https:\/\/www.novaliq.com\/press-releases\/2024\/10\/02\/novaliq-and-laboratoires-thea-announce-partnership-and-eu-approval-for-vevizye-ciclosporin-0-1-eye-drops-solution\/."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/OPTH.S126668","article-title":"Dry eye syndrome: Developments and lifitegrast in perspective","volume":"12","author":"Lollett","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/aos.15159","article-title":"Hyaluronic acid in the treatment of dry eye disease","volume":"100","author":"Hynnekleiv","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1186\/s12967-026-08609-w","article-title":"Effectiveness of a heparin-like glycosaminoglycan from snail mucus in a murine model of dry eye","volume":"24","author":"Ou","year":"2026","journal-title":"J. Transl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2147\/OPTH.S308088","article-title":"Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion","volume":"15","author":"Matossian","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s40123-025-01101-6","article-title":"Hydroxypropyl-Methylcellulose and GlicoPro\u00ae Eyedrops in the Treatment of Dry Eye Disease: In Vitro and Clinical Study","volume":"14","author":"Villani","year":"2025","journal-title":"Ophthalmol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40123-025-01302-z","article-title":"Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Undergoing Cataract Surgery: A Prospective Multicenter Study","volume":"15","author":"Hovanesian","year":"2026","journal-title":"Ophthalmol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"110755","DOI":"10.1016\/j.cellsig.2023.110755","article-title":"Targeting Ca2+-dependent pathways to promote corneal epithelial wound healing induced by CISD2 deficiency","volume":"109","author":"Sun","year":"2023","journal-title":"Cell. Signal."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5693\/djo.01.2019.02.005","article-title":"TThe use of self-retained, cryopreserved amniotic membrane for the treatment of Sj\u00f6gren syndrome: A case series","volume":"25","author":"Shafer","year":"2019","journal-title":"Digit. J. Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19279","DOI":"10.1038\/s41598-023-46671-2","article-title":"Efficacy and safety of platelet-rich plasma and autologous-serum eye drops for dry eye in primary Sj\u00f6gren\u2019s syndrome: A randomized trial","volume":"13","author":"Kang","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_38","unstructured":"(2026, July 20). Novartis Ianalumab First Drug to Reduce Disease Activity and Patient Burden in Sj\u00f6gren\u2019s Disease Phase III Trials. Available online: https:\/\/www.novartis.com\/news\/media-releases\/novartis-ianalumab-first-drug-reduce-disease-activity-and-patient-burden-sjogrens-disease-phase-iii-trials."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Huo, Y., Wan, Q., Hou, X., Zhang, Z., Zhao, J., Wu, Z., and Jin, X. (2022). Therapeutic Effect of Intense Pulsed Light in Patients with Sj\u00f6gren\u2019s Syndrome Related Dry Eye. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051377"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/ICO.0000000000002837","article-title":"TearCare for the Treatment of Meibomian Gland Dysfunction in Adult Patients with Dry Eye Disease: A Masked Randomized Controlled Trial","volume":"41","author":"Gupta","year":"2022","journal-title":"Cornea"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e70389","DOI":"10.1111\/jocd.70389","article-title":"Intense Pulsed Light Improves Facial Telangiectasia and Acne-Induced Post-Inflammatory Erythema in Systemic Lupus Erythematosus Patient: A Case Report","volume":"24","author":"Li","year":"2025","journal-title":"J. Cosmet. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7272\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:28:57Z","timestamp":1790076537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":41,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15187272"],"URL":"https:\/\/doi.org\/10.3390\/jcm15187272","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}